TC
The startup develops a cell regenerative method utilizing regenerative T cells derived from human induced pluripotent stem (iPS) cells to create personalized immuno-cell therapies. This approach targets cancer and infectious diseases, providing tailored treatment options for patients.
Updated 3 months ago
Funding
$27.1M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Founder details are not available yet.
Product
Features
- The startup develops a cell regenerative method utilizing regenerative T cells derived from human induced pluripotent stem (iPS) cells to create personalized immuno-cell therapies. This approach targets cancer and infectious diseases, providing tailored treatment options for patients.